Carboplatin, Etoposide, Ifosfamide — Competitive Intelligence Brief

Carboplatin, Etoposide, Ifosfamide (Carboplatin, Etoposide, Ifosfamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

marketed Combination chemotherapy regimen DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition) Oncology Small molecule

Target snapshot

Carboplatin, Etoposide, Ifosfamide (Carboplatin, Etoposide, Ifosfamide) — University Hospital Muenster. This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carboplatin, Etoposide, Ifosfamide TARGET	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

1. Sun Yat-sen University · 5 drugs in this class
2. Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
3. Hoffmann-La Roche · 2 drugs in this class
4. University Hospital, Bordeaux · 2 drugs in this class
5. Beijing Friendship Hospital · 1 drug in this class
6. Centre Hospitalier Universitaire Dijon · 1 drug in this class
7. Amgen · 1 drug in this class
8. Chungnam National University Hospital · 1 drug in this class
9. AstraZeneca · 1 drug in this class
10. Children's Cancer Group, China · 1 drug in this class